- Home
- FATE
as 01-17-2025 4:00pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 406.5M | IPO Year: | 2013 |
| Target Price: | $6.75 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $8.83 | Next Earning Date: | 02-24-2025 |
| Revenue: | $13,447,000 | Revenue Growth: | -87.34% |
| Revenue Growth (this year): | -78.47% | Revenue Growth (next year): | -70.61% |
Stock Insider Trading Activity of Fate Therapeutics Inc. (FATE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TAHL CINDY | FATE | See Remarks | Jan 10 '25 | Sell | $1.55 | 5,654 | $8,763.70 | 336,707 | |
| Valamehr Bahram | FATE | President and CEO | Jan 10 '25 | Sell | $1.54 | 8,705 | $13,405.70 | 349,364 | |
| Redmile Group, LLC | FATE | Director10% Owner | Dec 20 '24 | Buy | $1.68 | 397,964 | $668,579.52 | 12,884,277 | |
| Redmile Group, LLC | FATE | Director10% Owner | Dec 20 '24 | Sell | $1.68 | 341,633 | $573,943.44 | 12,486,313 |
Latest Fate Therapeutics Inc. News
FATE Breaking Stock News: Dive into FATE Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zacks
a month ago
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
MT Newswires
a month ago
Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits
GlobeNewswire
a month ago
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
GlobeNewswire
2 months ago
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Pharmaceutical Technology
2 months ago
Fate Therapeutics makes Bob Valamehr president and CEO
GlobeNewswire
2 months ago
Fate Therapeutics Announces Leadership Transition
GlobeNewswire
2 months ago
Fate Therapeutics to Present at Upcoming December Investor Conferences
Compare FATE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.